Your browser doesn't support javascript.
loading
A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age.
Christensen, Shane; Bouguermouh, Salim; Ilangovan, Kumar; Pride, Michael W; Webber, Chris; Lockhart, Stephen P; Shah, Rupal; Kitchin, Nicholas; Lamberth, Erik; Zhang, Haiying; Gao, Qi; Brock, Linda; Anderson, Annaliesa S; Gruber, William C.
Afiliação
  • Christensen S; J. Lewis Research, Salt Lake City, UT, USA.
  • Bouguermouh S; Pfizer Inc, Pearl River, NY, USA. Electronic address: salim.bouguermouh@pfizer.com.
  • Ilangovan K; Pfizer Inc, Collegeville, PA, USA.
  • Pride MW; Pfizer Inc, Pearl River, NY, USA.
  • Webber C; Pfizer Ltd, Hurley, UK.
  • Lockhart SP; Pfizer Ltd, Hurley, UK.
  • Shah R; Pfizer Inc, Pearl River, NY, USA.
  • Kitchin N; Pfizer Ltd, Hurley, UK.
  • Lamberth E; Pfizer Inc, Collegeville, PA, USA.
  • Zhang H; Pfizer Inc, Collegeville, PA, USA.
  • Gao Q; Pfizer Inc, Collegeville, PA, USA.
  • Brock L; Pfizer Inc, Pearl River, NY, USA.
  • Anderson AS; Pfizer Inc, Pearl River, NY, USA.
  • Gruber WC; Pfizer Inc, Pearl River, NY, USA.
Vaccine ; 41(50): 7548-7559, 2023 Dec 07.
Article em En | MEDLINE | ID: mdl-37977942
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Clostridioides difficile Limite: Aged / Aged80 / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Clostridioides difficile Limite: Aged / Aged80 / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article